Updates from the Advanced and Cell Therapies and Haematology teams within Manchester ECMC

09 Dec 2020
The Advanced and Cell Therapies team within Manchester ECMC led by Prof. Fiona Thistlethwaite has established the following: 
  • A growing portfolio with 6 ATMP trials open to recruitment for different solid tumours. Several trials in set-up opening by the end of the year.
  • A tailored ATMP Education induction for the NIHR Clinical Research Facility nurses.
  • First patient Apheresed in EUROPE for the GSK Ignyte Trial for Synovial Sarcoma. The patient was dosed in October using genetically engineered NY-ESO-1-Specific T cells.
 
The Haematology team, has recently appointed Dr Emma Searle as Consultant Haematologist - Early Phase Clinical Trials & Honorary Senior Lecturer within Manchester ECMC.  The team achieved a UK first in September 2020 with the dosing of a patient in the Phase I, open label, non-randomised, non-comparative, multicentre study, evaluating S65487, a Bcl-2 inhibitor intravenously administered, in patients with Relapse or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia.